Oncoclínicas do Brasil Serviços Médicos (ONCO3) Q1 2025 earnings summary

Executive summary

• Strategic focus on cash flow preservation and generation led to a R$131.8M year-over-year improvement in free cash flow, with internal adjustments and a more selective commercial policy slowing revenue growth and compressing margins.

• Commercial strategy prioritized higher revenue-to-cash conversion and client diversification, reducing exposure to payers with lower cash conversion and impacting top-line growth.

• Cost and expense reduction initiatives since Q3 2024 yielded over R$34M in savings in Q1 2025.

• Revenue diversification and new partnerships are ongoing, contributing to a healthier revenue mix.

• Largest private oncology provider in Brazil, operating 146 units with 9.1% market share and over 2,900 oncology specialists.

Financial highlights

• Gross revenue in Q1 2025 was R$1,658.1M, up 2.3% year-over-year; LTM gross revenue reached R$6.8B, up 10% year-over-year.

• Net revenue for LTM Q1 2025 was R$6.3B, up 10.7% year-over-year; Q1 2025 net revenue up 2.4% vs. Q1 2024.

• Adjusted EBITDA (Ex-LTIP) in Q1 2025 was R$134.3M (9.0% margin), down from R$240.2M (16.5%) in Q1 2024.

• Net loss Ex-LTIP was R$128M in Q1 2025, compared to net income of R$25.4M in Q1 2024.

• Free cash flow improved to R$10.7M in Q1 2025 from negative R$151.7M in Q1 2024.

Outlook and guidance

• Management expects margin and revenue growth to stabilize as the adjustment cycle concludes, with no further significant reductions in average ticket anticipated.

• Price readjustments (CMED) and new partnerships, such as with APIVIDA and Santa Group, are expected to positively impact future results.

• Continued focus on cash flow generation and client diversification, expecting further improvements in revenue-to-cash conversion.